Molecular Templates, Inc. (MTEM) News

Molecular Templates, Inc. (MTEM)

Today's Latest Price: $11.79 USD

0.74 (6.70%)

Updated Jan 19 4:00pm

Add MTEM to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

StocksNews Articles for MTEM

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest MTEM News From Around the Web

Below are the latest news stories about Molecular Templates Inc that investors may wish to consider to help them evaluate MTEM as an investment opportunity.

Molecular Templates updates on study of MT5111, plans breast cancer expansion cohort in 1H21

Molecular Templates (MTEM) provides an update on the Phase 1 study for MT5111, a HER2 targeted engineered toxin bodies ((ETB)). To date, 16 study subjects have been treated in the dose escalation portion of this study. Five cohorts (0.5, 1.0, 2.0, 3.0, and 4.5 μg/kg/week) have been successfully completed and the...

Seeking Alpha | December 22, 2020

Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study

Phase 1 Study Dose Escalation Ongoing in All HER2 Positive Tumor Types HER2 Positive Breast Cancer Expansion Cohort Planned to be Initiated in 1H21 Expansion Cohorts in Additional Tumors Types to Begin When MTD or Recommended Phase 2 Dose is ReachedAUSTIN, Texas, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today provided an update on the Phase 1 study for MT5111, MTEM’s HER2 targeted ETB.To date, 16 study subjects have been treated in the dose escalation portion of this study. Five cohorts (0.5, 1.0, 2.0, 3.0, and 4.5 μg/kg/week) have been succ...

Yahoo | December 21, 2020

Is MTEM A Good Stock To Buy Now According To Hedge Funds?

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]

Yahoo | December 19, 2020

Molecular Templates, Inc. (NASDAQ:MTEM) Major Shareholder Purchases $1,077,500.00 in Stock

Molecular Templates, Inc. (NASDAQ:MTEM) major shareholder Target N. V. Biotech purchased 125,000 shares of the business’s stock in a transaction on Wednesday, December 9th. The shares were acquired at an average price of $8.62 per share, with a total value of $1,077,500.00. Following the completion of the transaction, the insider now owns 6,060,331 shares of […]

Watchlist News | December 14, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Molecular Templates, Inc. - MTEM

NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Molecular Templates, Inc. (“Molecular” or the “Company”) (NASDAQ: MTEM).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.  The investigation concerns whether Molecular and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On November 6, 2020, Molecular Templates disclosed that the U.S. Food and Drug Administration (“FDA”) had placed the Company’s “MT-3724 clinical studies on partial clinical hold following a treatment-related fatality in one subject who experienced Grade 5 capillary leak syndrome i...

Yahoo | December 1, 2020

Molecular Templates to Participate in Upcoming Virtual Investor Conferences

AUSTIN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage…

GlobeNewswire | November 16, 2020

Oppenheimer Sees These 3 Stocks Skyrocketing Over 100%

The U.S. presidential election has come to a close, and Wall Street isn’t opposed to the administration change. Last week saw the S&P 500 notch its second-best performance during an election week on record, even as Trump’s chances of getting re-elected became slimer and slimer.Weighing in for Oppenheimer, Chief Investment Strategist John Stoltzfus noted, “What appears clear so far is that the equity markets are not averse to a change of administration stateside at least so long as the Republicans maintain control over the Senate. Checks and balances ‘on the Hill’ have been known to be important to investors over the course of history. The present in our view is no exception.”There is, however, some uncertainty surrounding the Senate, with the two runoff elections for seats in Georgia sc...

Yahoo | November 10, 2020

US$17.40: That's What Analysts Think Molecular Templates, Inc. (NASDAQ:MTEM) Is Worth After Its Latest Results

Shareholders might have noticed that Molecular Templates, Inc. (NASDAQ:MTEM) filed its quarterly result this time last...

Yahoo | November 8, 2020

The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 5) * Abbott Laboratories (NYSE: ABT) * Amicus Therapeutics, Inc. (NASDAQ: FOLD) * Anavex Life Sciences Corp (NASDAQ: AVXL) * Anchiano Therapeutics Ltd - ADR (NASDAQ: ANCN) * Aptevo Therapeutics Inc (NASDAQ: APVO) * Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) * Bio-Rad Laboratories, Inc. (NYSE: BIO) * BIO-TECHNE Corp (NASDAQ: TECH) (reacted to its third-quarter results) * BioLife Solutions Inc (NASDAQ: BLFS) * Catalent Inc (NYSE: CTLT) (announced a manufacturing partnership with Taysha Gene Therapies Inc (NASDAQ: TSHA)) * Denali Therapeutics Inc (NASDAQ: DNLI) * Eidos Therapeutics Inc (NASDAQ: EIDX) * Fate Therapeutics Inc (NASDAQ: FATE)...

Yahoo | November 6, 2020

Molecular Templates (NASDAQ:MTEM) Rating Lowered to Sell at BidaskClub

Molecular Templates (NASDAQ:MTEM) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Tuesday, BidAskClub reports. MTEM has been the subject of a number of other reports. ValuEngine raised shares of Molecular Templates from a “hold” rating to a “buy” rating in a research […]

Transcript Daily | October 22, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7242 seconds.